BOSTON, MA, August 13, 2014 /24-7PressRelease/ -- Tomi Sawyer, Distinguished Scientist & Head of Peptide Drug Discovery & Innovative Technologies at Merck will keynote present at 2nd Protein-Protein Interaction Conference to be held on October 23-24, 2014 in Boston, MA by GTC.

GTCbio's upcoming 2nd Protein-Protein Interaction Conference to be held on October 23-24, 2014 in Boston, MA will have sessions that cover novel techniques, new algorithms and databases for PPIs, and potential druggable sites for disrupting protein-protein interactions. Attendees will gain an enhanced understanding of the molecular basis of peptide and protein aggregation and insights into the design of inhibitors of peptide and protein aggregation. Some focused topics we will discuss is how inhibiting PPIs can be a promising therapeutic target, PPI interactions within the TNF family, the first small-molecule inhibitors for the CD40-CD40L, and much more including the fundamental aspects of protein-protein interactions. For more information, please visit: http://www.gtcbio.com/conferences/ppi-overview

This conference is part of the larger Protein Discovery Summit 2014, which consists of the following co-located conferences:

3rd Protein Kinases & Drug Design 2nd Protein Expression, Characterization & Purification2nd Antibody & Protein Therapeutics2nd Protein-Protein Interaction

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTCbio (Global Technology Community), LLC, is a privately-held company founded in 2002.